Legend Biotech (LEGN) Q1 2026: CARVICTI Ex-U.S. Sales Jump 200% as Early-Line Adoption Accelerates
Legend Biotech’s Q1 2026 results spotlighted surging global demand for CARVICTI, with ex-U.S. revenues up sharply and early-line usage gaining ground in the U.S. Margins dipped on one-time manufacturing expansion costs but are expected to rebound, as the company’s pipeline advances and in vivo CAR-T programs mature. Management reaffirmed a near-term path to profitability and highlighted durable commercial and R&D momentum heading into the rest of the year.
Summary
- CARVICTI’s Early-Line Penetration Accelerates: U.S. second and third-line adoption rose to 41% of apheresis volume, signaling a shift in treatment paradigms.
- One-Time Manufacturing Costs Compress Margins: Gross margin temporarily declined but is set to recover as new capacity is absorbed.
- In Vivo CAR-T Pipeline Progresses: Phase 1 trials advance, with initial data on track for mid-year disclosure.
Business Overview
Legend Biotech is a global cell therapy company focused on developing and commercializing CAR-T therapies, which are engineered T-cell treatments for cancer and autoimmune diseases. The company’s core revenue driver is CARVICTI, a CAR-T therapy for multiple myeloma, commercialized in partnership with Johnson & Johnson. Additional pipeline programs include next-generation in vivo CAR-T candidates targeting hematologic malignancies and autoimmune indications. The business model combines product sales, collaboration revenue, and milestone payments, with a growing emphasis on global market expansion and R&D-driven innovation.
Performance Analysis
Legend Biotech delivered a quarter marked by robust commercial execution and pipeline advancement, anchored by CARVICTI’s 62% year-over-year net trade sales growth. U.S. sales grew 36% YoY, while ex-U.S. sales surged over 200%, now spanning 18 global markets and more than 300 treatment sites. Sequential growth (Q4 to Q1) was 8%, with U.S. demand driven by earlier line adoption and new site activations, and ex-U.S. growth fueled by European expansion and recent launches.
Gross margin on product sales fell to 41% from 57% in Q4, attributed to one-time expenses from manufacturing site expansion at Raritan and ongoing ramp at Tech Lane. Management expects margins to rebound above 50% in Q2 as these costs normalize and utilization increases. R&D spend remained focused on in vivo CAR-T and next-gen programs, while SG&A investment supported commercial scaling. Adjusted net loss narrowed significantly, and the company ended the quarter with $835 million in cash and no long-term debt, reinforcing liquidity and capital flexibility.
- Early-Line Mix Shift: 41% of U.S. CARVICTI apheresis volume now comes from second and third-line patients, up from 29% a year ago, reflecting physician confidence and community adoption.
- Manufacturing Reliability: Achieved a 99% success rate and median 29-day turnaround, supporting both scale and earlier-line penetration.
- Operating Leverage: Revenue growth is translating into narrowing operating losses and a clear path to adjusted profitability in 2026.
Legend’s financial and operational profile is increasingly defined by scale, disciplined reinvestment, and a pipeline poised to generate new value inflections.
Executive Commentary
"Legend is the largest standalone cell therapy company anchored by Carvicti, our market-leading and profitable CAR-T therapy for multiple myeloma. In parallel, we're working to advance Carvicti into the first-line treatment setting to help reach more patients and further broaden its long-term opportunity."
Ying Huang, Chief Executive Officer
"We anticipate company-wide profitability on an adjusted basis in 2026 and expect continued margin improvements from our ongoing expense discipline. Looking ahead to the second quarter, we expect gross margin to be back over 50% as the economies of scale from our manufacturing investment are realized with increasing utilization."
Carlos Santos, Chief Financial Officer
Strategic Positioning
1. CARVICTI Early-Line Expansion
Legend is aggressively driving CARVICTI adoption into earlier lines of therapy, with nearly half of U.S. patients now treated in second or third line. This shift is enabled by strong clinical data, community center onboarding, and reliable manufacturing, positioning the therapy as a foundational option and building a durable competitive moat ahead of potential BCMA CAR-T rivals and bispecific competitors.
2. Global Commercial Footprint Scaling
International growth is accelerating, with CARVICTI now available in 18 markets and supported by over 300 treatment sites. The ramp in ex-U.S. sales demonstrates the scalability of Legend’s manufacturing and distribution model and provides insulation against U.S.-centric competitive risks.
3. Manufacturing Optimization and Capacity Investment
Legend’s operational focus is on maximizing manufacturing reliability and throughput, evidenced by a 99% success rate and rapid turnaround. One-time costs from facility expansions are expected to yield economies of scale, underpinning future margin expansion as volumes rise.
4. In Vivo CAR-T Pipeline Advancement
Legend’s pipeline strategy is shifting toward in vivo CAR-T platforms, with multiple first-in-human trials launched and initial data readouts expected mid-year. The company is targeting both hematologic malignancies and autoimmune diseases, aiming for differentiated efficacy and safety profiles through dual-targeting and novel vector technology.
5. Financial Discipline and Profitability Trajectory
Legend maintains a strong balance sheet and disciplined capital allocation, reinvesting CARVICTI profits into pipeline innovation while guiding toward adjusted profitability in 2026. The absence of long-term debt enhances flexibility for business development and manufacturing investments.
Key Considerations
This quarter marks a strategic inflection for Legend, with commercial momentum, manufacturing scale, and pipeline progress converging. Investors should weigh both the durability of CARVICTI’s growth and the emerging value of the in vivo platform as competitive and market dynamics evolve.
Key Considerations:
- Early-Line Adoption Momentum: Sustained growth in second and third-line usage suggests a lasting shift in myeloma treatment patterns.
- Manufacturing Scale and Reliability: Operational discipline is enabling both expansion and margin recovery, supporting long-term growth.
- Pipeline Readouts as Catalysts: Upcoming in vivo CAR-T data could redefine Legend’s R&D narrative and valuation.
- Competitive Landscape Evolution: The large, underpenetrated second-to-fourth-line myeloma market allows for multiple winners, but new entrants and bispecifics remain a watchpoint.
- Profitability Path Clarity: Adjusted profitability is in sight, contingent on margin normalization and continued sales momentum.
Risks
Legend faces execution risks around manufacturing scale-up, especially as new facilities come online and global demand rises. Competitive threats from other BCMA-targeted therapies and bispecifics could pressure market share and pricing, particularly if new data shifts physician preferences. Clinical pipeline milestones, especially in vivo CAR-T efficacy and safety, represent binary risk points with significant valuation implications. Regulatory, reimbursement, and operational complexity in new global markets may introduce volatility as the company scales.
Forward Outlook
For Q2 2026, Legend guided to:
- Gross margin recovery to above 50% as manufacturing expansion costs subside
- Continued sequential growth in both U.S. and ex-U.S. CARVICTI sales
For full-year 2026, management maintained guidance:
- Adjusted company-wide profitability by year-end
Management emphasized:
- Ongoing momentum in early-line CARVICTI adoption and community center onboarding
- Anticipated in vivo CAR-T data disclosures at major medical meetings mid-year
Takeaways
Legend Biotech’s Q1 2026 results underscore the company’s unique position at the intersection of commercial cell therapy leadership and next-generation pipeline innovation.
- Early-Line Penetration Drives Growth: The shift toward second and third-line CARVICTI usage is unlocking new patient pools and reinforcing community channel strength, supporting durable revenue expansion.
- Margin Recovery Hinges on Manufacturing Absorption: One-time costs compressed Q1 margins, but operational execution and scale are expected to restore profitability trajectory in coming quarters.
- Pipeline Inflection Approaching: Initial in vivo CAR-T clinical data and ongoing phase 3 CARVICTI studies represent critical catalysts for Legend’s long-term growth narrative and competitive positioning.
Conclusion
Legend Biotech enters the rest of 2026 with clear commercial momentum, a robust balance sheet, and a maturing pipeline that could reshape its long-term opportunity set. Margin normalization and pivotal data readouts will be key to sustaining investor confidence as the company transitions from single-product scale-up to broader platform leadership.
Industry Read-Through
Legend’s accelerating early-line CAR-T adoption and international expansion signal a broader shift in cell therapy market dynamics, with community channel penetration and manufacturing reliability emerging as decisive factors for durable leadership. For the cell therapy sector, Legend’s operational model and in vivo pipeline progress highlight the importance of scalable infrastructure and differentiated technology in maintaining growth as competition intensifies. Other players in oncology and autoimmune therapeutics should note the rising bar for clinical efficacy, safety, and operational execution as CAR-T moves earlier in treatment paradigms and into new indications.